Journal Mobile Options
Table of Contents
Vol. 5, No. 4, 2005
Issue release date: October–December 2005
Section title: Review
Heart Drug 2005;5:220–229
(DOI:10.1159/000089603)

Nicorandil – Review of Pharmacological Properties and Clinical Applications

Schmid J.-P. · Schroeder V.
Swiss Cardiovascular Centre Bern, Cardiovascular Prevention and Rehabilitation, University Hospital (Inselspital), Bern, Switzerland

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 4/21/2005
Accepted: 7/25/2005
Published online: 12/22/2005
Issue release date: October–December 2005

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 0

ISSN: 1422-9528 (Print)
eISSN: 1424-0556 (Online)

For additional information: http://www.karger.com/HED

Abstract

Nicorandil is a drug which has been developed as an anti-anginal medication. Its structure is characterized by a dual mechanism of action. The nicotinamide moiety acts as an opener of ATP-sensitive potassium channels, whereas the NO2 group explains its nitrate-like properties. The nitric oxide-like action leads to a dilatation of the large coronary arteries, whereas its potassium channel opening action is responsible for the dilatation of coronary resistance vessels. Nicorandil has also been found to dilate veins, enabling it to decrease both preload and afterload and to increase coronary blood flow. The ATP-sensitive potassium channel opening mimics preconditioning in the absence of ischemia and may therefore exert cytoprotective effects. These have been thought to be the reason for a reduction in major coronary events and all cardiovascular events of nicorandil in addition to a specific anti-anginal medication in the Impact Of Nicorandil in Angina study. This review summarizes the pharmacologic properties of nicorandil and assesses its actual place in different cardiovascular disease states.

© 2005 S. Karger AG, Basel


  

Author Contacts

Jean-Paul Schmid, MD
Cardiovascular Prevention and Rehabilitation
Swiss Cardiovascular Centre Bern, University Hospital (Inselspital)
CH–3010 Bern (Switzerland)
Tel. +41 31 632 89 72, Fax +41 31 632 89 77, E-Mail jean-paul.schmid@insel.ch

  

Article Information

Received: April 21, 2005
Accepted after revision: July 25, 2005
Published online: December 7, 2005
Number of Print Pages : 10
Number of Figures : 1, Number of Tables : 0, Number of References : 92

  

Publication Details

Heart Drug (Excellence in Cardiovascular Trials)

Vol. 5, No. 4, Year 2005 (Cover Date: October-December 2005)

Journal Editor: Atar, D. (Oslo)
ISSN: 1422–9528 (print), 1424–0556 (Online)

For additional information: http://www.karger.com/HED


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 4/21/2005
Accepted: 7/25/2005
Published online: 12/22/2005
Issue release date: October–December 2005

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 0

ISSN: 1422-9528 (Print)
eISSN: 1424-0556 (Online)

For additional information: http://www.karger.com/HED


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.